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High-Throughput Screening Identifies
Inhibitors of the SARS Coronavirus Main Proteinase
in the first step of the formation of the crucial replication-
transcription complex. The activity of 3CLpro, so named
for its similarity to 3C proteinases of Picornaviridae [14],
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Jonathan D. Cechetto,1 Lindsay D. Eltis,2,*
and Eric D. Brown1,* is an attractive target for the development of therapeu-
tics against SARS due to its fundamental role in viral1McMaster High Throughput Screening Laboratory
Department of Biochemistry replication. Homology modeling with other 3CLpro’s [12,
15], X-ray crystallography [13], and a recent mutagene-McMaster University
Hamilton, Ontario L8N 3Z5 sis study [16] have identified 3CLpro as a cysteine prote-
ase with a Cys-His catalytic dyad in the active site.Canada
2 Departments of Microbiology and Biochemistry Structure-based sequence alignments of pp1a and
pp1ab of SARS-CoV with the equivalent polyproteinsUniversity of British Columbia
Vancouver, British Columbia V6T 1Z3 from human coronavirus 229E (HCoV), porcine transmis-
sible gastroenteritis virus (TGEV), bovine coronavirusCanada
(BCoV), and avian infectious bronchitis virus (IBV) have
identified the consensus sequence for proteolysis as
(S, T, V, P, A)-(L, I, V, F, M)-Q/(A, S, G, N, C) [12]. In vitroSummary
studies have confirmed the ability of 3CLpro to process
sites of this type, and that the proteinase has the highestThe causative agent of severe acute respiratory syn-
drome (SARS) has been identified as a novel coronavi- specificity for the cleavage sites flanking 3CLpro in the
pp1a/pp1ab polyprotein [11, 17].rus, SARS-CoV. The main proteinase of SARS-CoV,
3CLpro, is an attractive target for therapeutics against A structural model of 3CLpro based on sequence ho-
mology with TGEV [12] as well as the solved crystalSARS owing to its fundamental role in viral replication.
We sought to identify novel inhibitors of 3CLpro to ad- structure [13] have both been used in a number of stud-
ies to dock substrate mimics [12, 13, 18] and for virtualvance the development of appropriate therapies in the
treatment of SARS. 3CLpro was cloned, expressed, and screening of collections of synthetic compounds, natu-
ral products, and approved antiviral therapies to evalu-purified from the Tor2 isolate. A quenched fluores-
cence resonance energy transfer assay was devel- ate their ability to inhibit 3CLpro [15, 19–22]. Compounds
identified as potential inhibitors of 3CLpro from theseoped for 3CLpro to screen the proteinase against 50,000
drug-like small molecules on a fully automated sys- studies include the HIV-1 protease inhibitor L-700,417
[15], the reverse transcriptase inhibitors calanolide Atem. The primary screen identified 572 hits; through a
series of virtual and experimental filters, this number and nevirapine [20], glycovir, an -glucosidase inhibitor
[20], sabadinine, a natural product [21], and the generalwas reduced to five novel small molecules that show
potent inhibitory activity (IC50  0.5–7 M) toward antiviral ribavirin [20] . Ribavirin has been shown to ex-
hibit anti-SARS-CoV activity in vitro, but at concentra-SARS-CoV 3CLpro.
tions that are cytotoxic [23]. At the onset of the initial
SARS outbreak, this compound was used as a first-lineIntroduction
defense both as a monotherapy [24] and in combination
with corticosteroids [25] or Kaletra (an approved HIVThe first wave of Severe Acute Respiratory Syndrome
(SARS) was successfully contained by the summer of protease inhibitor) [24]; however, it is now generally be-
lieved that ribavirin is not an effective treatment for SARS2003 [1], but not until close to 8500 people worldwide
were infected, and over 900 had died [2]. Upon the emer- ([26, 27] and references therein). At the time of writing,
it is not known whether the other compounds identifiedgence of this syndrome, international response was
quick to identify and characterize its causative agent as through virtual means have yet been tested with 3CLpro
or SARS-CoV to evaluate their actual inhibitory capabil-a novel coronavirus, SARS-CoV [3–7]. The reemergence
ities.of SARS in the Guangdong province of China in Decem-
Several in vitro screens have also been recently re-ber 2003 [8] and the spring of 2004 [9], while not neces-
ported that have assessed the ability of existing protein-sarily indicative of another global outbreak, illustrates
ase inhibitors to inhibit replication of SARS-CoV and,the need to continue efforts to study this virus and de-
in some cases, 3CLpro specifically. The HIV-1 proteasevelop appropriate therapeutics for its treatment.
inhibitors indinavir, saquinavir, ritonavir, lopinavir, TYA5,SARS-CoV is an enveloped, positive-stranded RNA
TYB5, and KNI-272 were shown to be ineffective at inhib-virus whose genome is predominated by two open read-
iting replication of SARS-CoV in vitro [23, 28]. Anothering frames that are connected by a ribosomal frameshift
HIV-1 protease inhibitor, nelfinavir, was shown to inhibitsite and that encode the two replicase proteins, pp1a
SARS-CoV replication with an EC50 of 48 nM [28], yet itand pp1ab [10, 11]. These polyproteins are cleaved by
has also been reported that complete inhibition of viralthe main proteinase 3CLpro [11] (also called Mpro [12, 13])
replication was not seen with compound concentrations
up to 10 M [23]. Another in vitro screen that similarly*Correspondence: ebrown@mcmaster.ca (E.D.B.); leltis@interchange.
tested a library of 500 protease inhibitors resulted inubc.ca (L.D.E.)
3 These authors contributed equally to this work. only one compound that inhibited 3CLpro; this molecule
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had been developed as a transition-state analog inhibi-
tor for HIV-1 protease and had a Ki of 0.6 M with
3CLpro [29].
Although a number of existing drugs that could poten-
tially act as inhibitors of 3CLpro were identified through
virtual screening, other than ribavirin, it is not known
how active these compounds actually are toward the
protease. Additionally, in vitro screening campaigns il-
lustrate that out of over 500 existing protease inhibitors,
only two were identified as active toward 3CLpro. These
findings illustrate the need to look toward the develop-
ment of innovative inhibitors for this protease. One such
study has recently identified unique keto-glutamine ana-
logs as inhibitors of 3CLpro with IC50’s in the low micromo-
lar range (J.C. Vederas, submitted). In an effort to ad-
vance this initiative, we sought to identify novel small
molecules that specifically target 3CLpro. In this paper,
we describe the cloning, expression, and purification of
3CLpro from the SARS-CoV Tor2 isolate, and subsequent
Figure 1. The Quenched-FRET Assay Used to Monitor 3CLpro Ac-screening campaign against a library of 50,000 small
tivitymolecules. We herein report the finding of five novel
(A) The substrate is a 9 amino acid peptide labeled with 2-aminoben-inhibitors of 3CLpro.
zoyl (Abz) and a nitro-tyrosine on either side of the scissile peptide
bond (dashed) to act as donor and acceptor, respectively, for FRET.
In the intact substrate, excited state energy of Abz is transferred to
Results and Discussion the nitro-tyrosine via FRET and fluorescence is quenched.
(B) Once the substrate is cleaved by 3CLpro, the donor and acceptor
In order to screen SARS-CoV 3CLpro against a library of are spatially separated; subsequent fluorescence from the Abz func-
tionality is not quenched and can be detected.50,000 compounds, it was necessary to use an activity
assay for the proteinase that could be adapted to an
automated system. Ideally, such an assay would (1) work
of kinetic data using the Abz-Tyr(NO2) substrate, theover a time scale of several minutes at most to facilitate
primary data were corrected for inner filter effect [31].the rapid evaluation of thousands of potential inhibitors;
This adjustment was essential as it was observed that(2) be homogeneous for ease of automation; and (3)
at even relatively low concentrations of substrate (2M),be sensitive to minimize background signal from the
the fluorescence of the cleaved product was signifi-presence of the compounds tested. Quenched fluores-
cantly quenched by the nitrotyrosine moiety of the intactcence resonance energy transfer (FRET) assays have
substrate.become a common tool to monitor proteinase activity
The Km for the Abz-Tyr(NO2) substrate with 3CLpro was[30] and fulfill the necessary criteria for use in an efficient
820  130 M (Figure 2A). This value is comparable toand robust high-throughput screening (HTS) campaign.
those seen recently for nonlabeled 11-mer peptides thatThe basis for such an assay is the modification of a
also mimic the cleavage sites of the natural substratespeptide substrate to include a fluorescent label and
of 3CLpro (0.286–1.94 mM) [17], implying that the labelsquencher on opposing sides of the proteinase cleavage
incorporated for FRET were not detrimental to the asso-site (Figure 1). Using this substrate, the activity of a
ciation between enzyme and substrate. The calculatedproteinase can be measured directly without the need
values of the apparent kcat and kcat/Km for the labeledfor additional steps to purify and/or characterize the
substrate were 1.01  0.09 min1 and 1.2  0.2 mM1products. This type of assay is also beneficial as it per-
min1 respectively, and were also similar to those re-mits enzymatic reactions to be monitored in real time
to obtain accurate reaction rates. This aspect of the
quenched-FRET assay is particularly attractive since, in
evaluating the activity of a proteinase in terms of a rate,
the potential for false negatives to occur in the screen
due to the presence of inherent fluorescence from the
compounds being tested is reduced.
Two fluorogenic peptide substrates were synthesized
to develop a continuous assay of 3CLpro proteolytic activ-
ity based on FRET. The peptides were designed princi-
pally on the sequences flanking 3CLpro in the polyprotein
and solubility considerations. A peptide incorporating
the anthranilate-nitrotyrosine donor-acceptor pair (Abz- Figure 2. Activity of 3CLpro with the Fluorogenic Peptide Substrate
SVTLQSG-Tyr(NO2)R) (Figure 1) was over an order of (A) Michaelis-Menton plot to determine Km and the observed kcat.magnitude more sensitive in FRET-based assays than (B) A plot of observed assay rates containing 100 M substrate and
the equivalent Edans-Dabcyl peptide (data not shown) varying concentrations of 3CLpro demonstrates assay linearity with
respect to proteinase concentration.and was the preferred substrate for HTS. In the analysis
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Figure 3. Plot of the Residual Activity of the Controls from the
Screen
High (Replicate 1, orange circles; Replicate 2, green diamonds) and
low (Replicate 1, red triangles; Replicate 2, blue squares) controls
are clustered around 100% and 0% residual activity, respectively.
The Z of 0.60 is reflected in the well-defined hit window.
Figure 4. Replicate Plot for the Primary Screen of SARS-CoV 3CLpro
ported for the 11-mer peptides (0.847–12.2 min1 and The outlined hit zone was defined as 50% residual enzyme activity.
0.202–10.6 mM1min1) [17]. These kinetic parameters
are reported as apparent values since it has been re-
cently shown [17, 32] that at the concentration of 3CLpro with each of the tested library compounds (Figure 4)
used in this study (1 M) much of the enzyme is thought also illustrates the quality of the screen in terms of the
to be monomeric, whereas it is the dimeric form of the reproducibility between the duplicate sets of data. This
enzyme that is believed to be catalytically competent. figure also indicates that 3CLpro appears to have been
For the purposes of screening, it is desirable to use the inhibited to some degree by a large number of com-
lowest concentration of substrate that yields a reliable, pounds. The cutoff to determine the hit threshold was
reproducible signal. It was found that assays using 100 set to 50% residual enzyme activity in order to focus
M of the fluorogenic peptide gave a strong signal that on the most potent inhibitors.
was linear with varying 3CLpro concentration (Figure 2B). Five hundred and seventy-two hits (1.1% hit rate) were
This enabled us to screen at substrate concentrations identified from the primary screen of 3CLpro. For the
well below Km, which is advantageous for identifying preliminary analyses of these hits, we opted to restrict
inhibitors that compete with substrate for the enzyme the number of compounds entering secondary screen-
active site [33] and are therefore more likely to be spe- ing by a series of virtual and experimental filters. The
cific toward 3CLpro. hits were first classified by recursive partitioning into
The compound library used to screen 3CLpro contained 126 groups based on similarities between molecular
50,000 small molecules with an average molecular mass structure and activity in the primary screen [37, 38].
of 325 g/mol. This particular collection was screened Within each of these groups, the compound that strongly
because of its high quality, diversity, drug-likeness [34], inhibited 3CLpro was chosen as a representative candi-
resupply availability, and past success with other targets date for further study in secondary analyses. The dose-
[35]. The campaign was run in duplicate in 384-well response curves of the 126 representative compounds
microplate format on a fully automated system. were determined using standard assay conditions (100
The statistical parameter Z, which is described as a M substrate, 1 M 3CLpro) and 90 nM–100 M of tested
measure of the quality of an HTS campaign [36], is de- compound. The dose-response relationship of 72 com-
fined as pounds resulted in the typical sigmoidal semilogarithmic
curve associated with desirable inhibitors; the 54 com-
1  Z 
(3c  3c)
|c  c|
(1) pounds that did not result in this typical curve were
filtered out.
To eliminate nonspecific inhibitors, the effect of thewhere c, c, c, and c are the standard deviations
() and averages () of the high (c) and low (c) controls. remaining 72 compounds on 3CLpro activity in the pres-
ence of bovine serum albumin (BSA) was determined.This value reflects both the error associated with the
controls of a screen, as well as the size of the “hit win- If the degree of inhibition of 3CLpro by a compound is
decreased in the presence of BSA, inhibition is not likelydow” (Figure 3). A Z of 0.5 or greater is indicative of a
quality screen with a well-defined hit window [36]. The to be targeted exclusively toward 3CLpro. These so-
called “promiscuous” inhibitors likely form aggregatesZ for the primary screen of SARS-CoV 3CLpro was 0.60
for each of the two replicates indicating that the assay in solution that nonspecifically absorb or adsorb the
target enzyme [39]. Only three compounds showed anyused to detect activity of 3CLpro was robust and amena-
ble to HTS. The replicate plot of residual enzyme activity marked reduction in enzyme inhibition in the presence
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Table 1. Some of the Functional Groups of the 69 Filtered Hits from the Screening Campaign that Are Potentially Reactive with the
Catalytic Thiol in the Active Site of 3CLpro
No. of Hits
General Structurea Group X Y Z in Groupb
1 O CH2 CH 10
2 O O CH 5
3 O O N 2
4 O N CH 9
5 S N CH 1
6 S N N 1
7 CBr2 — — 1
8 O — — 5
9 N — — 12
10 S — — 5
11 S — — 4
12 N — — 1
13 — — — 2
14 — — — 6
15 — — — 16
a R1, R2, and R3 are a variety of aromatic and aliphatic substituents.
b The sum of the number of compounds in each group is greater than 69 as several compounds contained more than one of the listed
functionalities.
of BSA, with the greatest effect being a decrease of though this renders such compounds as unlikely drug
candidates, they may be useful in studying the activeonly 20%; these compounds were removed from the
prospective inhibitor pool. site architecture of 3CLpro. Of the remaining 69 candidate
inhibitors, the inhibitory action of 5 of these was notThe remaining 69 potential candidates were predomi-
nated by compounds with at least one potentially reac- significantly affected by the inclusion of 1 mM DTT;
these were selected for further characterization.tive center (Table 1). The thiol side chain of the active
site cysteine of 3CLpro is necessarily a good nucleophile The dose-response curves for these five compounds
with 3CLpro yielded IC50 values of 0.5–7 M (Figure 5).and therefore has the capacity to combine with a variety
of electrophilic functionalities to form covalent adducts. To evaluate the selectivity of each compound, we inves-
tigated their ability to inhibit four other proteinases withThis reaction is the basis for several classes of existing
peptidic inhibitors of cysteine proteases which include varying structural and mechanistic relatedness to SARS-
CoV 3CLpro. The Hepatitis A virus (HAV) 3Cpro, like all-	-unsaturated ketones, esters, and amides [40, 41]
(Table 1, 1–4) and nitriles [42] (Table 1, 15). In addition, picornaviral 3Cpros, is similar in structure, mechanism,
and substrate specificity to 3CLpro [11, 14, 45]. The Hepa-N-substituted maleimides (Table 1, 14) have long been
recognized as being reactive toward thiols in general, titis C Nonstructural 3 proteinase (NS3pro) and chymo-
trypsin are serine proteases with the same two 	-barreland cysteine proteases in particular [43]. The two identi-
fied sulfur containing compounds (Table 1, 13) are also fold as 3CLpro [13, 46]. Finally, papain is a paradigm
cysteine proteinase with an active site Cys/His/Asp ca-capable of forming disulfide linkages with the catalytic
thiol of 3CLpro to inactivate the enzyme [44] The re- talytic triad whose structural fold does not resemble
that shared by chymotrypsin, NS3pro, 3CLpro, and 3Cpro.maining carbonyl functionalities and corresponding ni-
trogen- and sulfur-containing analogs listed in Table 1, It was difficult in some cases to obtain a full dose-
response curve for every inhibitor with each of the pro-5–12, may also have enough electrophilic character to
promote the nucleophilic attack of the active site thiol teinases due to interfering compound fluorescence and/
or compound insolubility under each of the assay condi-of 3CLpro. Due to the potential inherent reactivity of the 69
candidate inhibitors, we sought to identify and eliminate tions. In such cases, if the lack of data at higher com-
pound concentrations precluded interpolation of a reli-those compounds whose high reactivity rendered them
nonspecific toward the active site of 3CLpro by including able IC50 value, the IC50 is reported as a lower limit (Table
2). Alternatively, those compounds for which enzyme1,4-dithio-D,L-threitol (DTT) in the inhibition reaction. A
reduction in the inhibition of 3CLpro by any candidate inhibition was not seen at the highest concentration
tested, are indicated accordingly. It is important to notecompound in the presence of DTT suggests that such
a compound would probably react nonspecifically with that in the absence of full mechanistic analyses, the IC50
values are intended to reveal profound differences inany biologically available thiol functionality [40, 41]. Al-
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Considering the mechanistic and structural relation-
ships between 3CLpro and HAV 3Cpro, and to a lesser
extent NS3pro, we were interested to learn that some of
the compounds showed highest activity against these
related enzymes. In addition to inhibiting 3CLpro with an
IC50 of 7 M, compound MAC-30731 was observed to
have relatively potent activity against HAV 3Cpro (IC50 
54 M) and NS3pro (IC50  71 M), with only weak impact
on chymotrypsin (IC50 
 800 M).
MAC-8120 and MAC-13985 also demonstrated inter-
esting selectivity profiles with good activity against
SARS-CoV 3CLpro (IC50 values were 4.3 and 7M, respec-
tively) and no detectable inhibition of any of the other
proteinases tested. These particular compounds, how-
ever, proved to be difficult in the assays of HAV 3Cpro
and NS3pro due to background fluorescence, and could
not be tested at concentrations greater than 5 M. Nev-
ertheless, no detectable inhibition was seen at that con-
centration, indicating that an IC50 for these molecules
would necessarily be much higher.
The protease selectivity data, therefore, point to two
molecules with apparent selectivity for 3CLpro, MAC-
8120 and MAC-13985. These may well be the most
promising leads for further mechanistic characterization
and optimization efforts toward a protease-based antivi-
ral for SARS-CoV. One molecule, MAC-30371, has an
interesting selectivity for the picornaviral-like protein-
ases and could prove to be a viable lead for this family
of proteolytic enzymes.Figure 5. Dose-Response Curves for the Five Secondary Hits from
the Screening Campaign A search of the literature for any studies involving the
IC50 values were extracted from the curves using nonlinear regres- five secondary hits showed that at present, none have
sion analysis (see Experimental Procedures). IC50 values for the five been identified as proteinase inhibitors. Of particular
secondary hits were 0.5  0.3 M (MAC-5576), 4.3  0.5 M (MAC- significance, however, is the finding that MAC-8120 has
8120), 7  2 M (MAC-13985), 2.6  0.4 M (MAC-22272), and 7 
been identified as an inhibitor of triosephosphate isom-3 M (MAC-30731). The corresponding structure of each compound
erase from Trypanosoma cruzi, T. brucei, human, andis shown on each dose-response curve.
yeast (IC50  56 M to 4 mM) [47]. This study examined
the inhibition of the isomerase by a series of substituted
potency to provide insight into the selectivity of the benzothiazoles, and indicated that MAC-8120 inter-
inhibitors, and to aid in their prioritization as leads for acted with cysteine residues on the enzyme that were
continuing studies. previously shown to be central in dimerization. This in-
Compound MAC-22272 showed the least selectivity teraction, although as yet uncharacterized, was reported
with respect to 3CLpro (IC50  2.6 M), as it was the only to perturb the contact interface of the subunits of the
inhibitor capable of inactivating all of the proteinases homodimer to inactivate the enzyme. It is therefore quite
studied, although the response with NS3pro (IC50 
 500 possible that MAC-8120 associates with the active site
M) was significantly lower than with the other enzymes. cysteine of 3CLpro in a similar manner to disrupt its cata-
MAC-5576 showed some selectivity toward those pro- lytic activity. The exact mechanism of inhibition of 3CLpro
teinases with a chymotrypsin-like fold, as it was seen by MAC-8120 and the remaining secondary hits requires
to inhibit 3CLpro (IC50  0.5 M), HAV 3Cpro (IC50  0.5 further study and characterization in order to evaluate
M), and chymotrypsin (IC50 13M), although no effect their potential to act as leads for the development of
was seen with NS3pro, which also shares this structural novel therapeutics against SARS-CoV, and potentially,
motif. Papain, which lacks this fold, was unaffected by other picornaviral-like proteinases. Additionally, the
MAC-5576. An important difference between 3CLpro and core structure of these compounds can be chemically
3Cpro is that the coronaviral enzyme is only functionally modified to improve key physical properties such as
active as a dimer whereas 3Cpro is active as a monomer potency and solubility.
in vitro. The interaction between the 3CLpro subunits is It is clearly evident that the 3CLpro screening campaign
sufficiently weak that disrupting the dimerization inter- has generated a wealth of data that can be mined for a
face has been proposed as a promising target for novel number of studies. While it was our intention to identify
antiviral agents [32]. In view of the relatedness between novel small molecules that would lead to the develop-
3CLpro and HAV 3Cpro, it is therefore likely that of the five ment of therapeutics effective against SARS-CoV, the
secondary hits, those that are also active toward HAV results generated by the screening campaign can be
3Cpro do not interact with 3CLpro at its dimer interface, applied to other types of studies of 3CLpro and related
proteinases including the picornaviral 3Cpro. To this end,but at a site that is common to both proteinases.
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Table 2. Summary of IC50 Values of the Five Secondary Hits with SARS-CoV 3CLpro and Four Other Proteases
IC50 (M)a
Compound Structure 3CLpro HAV 3Cpro NS3pro Chymb Papain
MAC-5576 0.5  0.3 0.54  0.09† N.I. (500)c 13  5 N.I. (500)
MAC-8120 4.3  0.5 N.I. (5) N.I. (5) N.I. (500) N.I. (500)
MAC-13985 7  2 N.I. (5) N.I. (5) N.I. (500) N.I. (500)
MAC-22272 2.6  0.4 0.9  0.1 
500d 29  12 18  9
MAC-30731 7  3 54  16 71  14 
800 N.I. (500)
a To calculate IC50 values, dose-response data were fit to a 3-parameter equation (Equation 2), excluding †, in which a 4-parameter equation
(Equation 3) was used (see Experimental Procedures).
b Bovine pancreas chymotrypsin.
c No inhibition seen at the concentrations of compound tested; highest concentration tested in brackets (in M).
d Protease inhibition was seen, but insufficient data were obtained to calculate a reliable IC50 value.
we have made the complete primary screening data set investigate their mode of inhibition of 3CLpro and their
potential to provide a basis for innovative antiviral ther-and corresponding compound structures available for
download from the McMaster HTS Lab (http://hts. apies.
By virtue of the number of molecules evaluated, thismcmaster.ca/sars). Interested parties are invited to re-
view the data and mine it for their own studies. campaign has resulted in an extensive data set. As
well as identifying inhibitors of 3CLpro, the primary data
from the screen can be utilized in numerous studies,Significance
such as identifying structure-activity relationships, by
others investigating 3CLpro in particular and other mainIn response to the initial SARS outbreak of 2003, a
proteinases in general. For this reason, the authorsconcerted effort by the international scientific commu-
have made the primary screening data set publiclynity identified the causative agent of this infection as
available in the hope that researchers will find thisa novel coronavirus, SARS-CoV. Characterization of
information useful in future studies.this virus and the development of appropriate thera-
pies soon followed and remains a continuing global
Experimental Procedureseffort. The main proteinase of SARS-CoV, 3CLpro, plays
a crucial role in viral replication and is therefore an
Chemicals and Reagents
excellent target for therapeutics effective in treating All chemicals were of analytical grade and used without further
SARS. Our contribution to the anti-SARS initiative was purification. Restriction enzymes were purchased from New En-
to employ a high-throughput screening strategy to gland Biolabs (Pickering, ON, Canada). All peptide substrates and
activating peptides were synthesized by the Peptide Synthesis Lab-identify small molecules that specifically target 3CLpro
oratory, NAPS Unit, University of British Columbia (Vancouver, BC,in order to generate new therapeutic leads. HTS is an
Canada).efficient and rapid means of assessing the effect of a
large number of compounds on a target of interest;
Strains, Media, and Growth
we feel that such campaigns should play an integral DNA was propagated using Escherichia coli DH5. The protease
part of any initial investigations undertaken to combat was expressed using E. coli GJ1158 [48] transformed with pT7-7
newly emerging infectious agents. derivatives [49]. E. coli strains were cultured at 37C and 250 rpm
in Luria-Bertani (LB) broth supplemented with the appropriate antibi-A quenched-FRET assay was developed and used
otics. For expression, E. coli GJ1158 was cultured in LB broth withto evaluate the activity of 3CLpro in the presence of
100 g/mL ampicillin.50,000 small drug-like molecules; of these com-
pounds, 572 were shown to inhibit 3CLpro. Utilizing a
Construction of Plasmids and Overexpression
series of filters, this number of compounds was re- DNA was manipulated using standard protocols [50]. A vector was
duced to five potent hits (IC50  0.5–7 M) that repre- designed to express 3CLpro as an N-terminal, cleavable his-tagged
protein. The expression vector was derived from pT7HP20, a deriva-sent novel leads. Secondary studies of these leads will
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tive of pT7-7 [49] containing an approximately 300 bp XbaI/HindIII substrate 2-aminobenzoyl-SVTLQSG-Tyr(NO2)-R. The rate of en-
zyme activity was determined by the increase in fluorescence uponfragment from pLEHP20 [51]. A plasmid containing the coding se-
quence of the SARS-CoV 3CLpro was a generous gift from Genome continuous monitoring of reactions in 384-well black microplates
(Nalge Nunc International, Rochester, NY) (excitation wavelength Sciences Centre (Vancouver, BC, Canada). The gene encoding
3CLpro was amplified by PCR using the following oligonucleotides: 330 nm, emission wavelength  420 nm). Total assay volume was
50 L, and contained 1 M 3CLpro, 100 M peptide substrate, 4.2%SPH (5-CCCAGCTAGCGGTTTTAGGAAAATGGCATTC-3) and 3SP
(5-TACGAAGCTTGTCGACTTATTGGAAGGTAACACCAGAGCA-3). dimethyl sulfoxide (DMSO) (v/v) (Sigma, Oakville, ON, Canada), and
100 mM potassium phosphate (pH 8.0) (Sigma), unless noted other-SPH introduces an NheI site (underlined) at the beginning of the
gene and 3SP introduces a HindIII site (underlined) and a stop codon wise. Reactions were done at room temperature, and were initiated
by the addition of substrate. Steady-state kinetic parameters were(boldface) at the end of the coding sequence. The PCR reaction
was performed using the Expand High Fidelity DNA polymerase evaluated using 16 M–1 mM substrate and 1 M 3CLpro; these data
were corrected for inner filter effect by the method of Liu et al. [31]system (Roche Applied Sciences, Laval, PQ, Canada) according to
the manufacturer’s instructions using an annealing temperature of with the use of Abz-SVRLQ to calculate correction factors.
50C. The resulting amplicon was digested with NheI and HindIII
and cloned in pT7HP20 yielding the expression plasmid pT7HSP1. Primary Screening
The cloned gene was sequenced using an ABI 373 Strech (Applied The screen of 3CLpro against 50,000 small molecules was fully auto-
Biosystems, Foster City, CA) using Big-Dye terminators to verify its mated with the use of a SAGIAN Core System (Beckman Coulter,
authenticity. The amplified gene and the original clone had a deletion Inc., Fullerton, CA) equipped with an ORCA arm for labware trans-
(corresponding to guanine at position 32 of the coding sequence). portation, a Biomek FX with a 96-channel head for liquid handling,
The mutation was repaired in pT7HSP1 using a convenient BsmI and an Analyst HT (Molecular Devices Corp., Sunnyvale, CA) for
site. Accordingly, the oligonucleotide S3CDM (5-GAAAATGGCATT fluorescence detection; the entire system was integrated through
CCCGTCAGGCAAAGTTGAAGG-3) contains the BsmI restriction SAMI (v. 3.5, Beckman Coulter). Reactions were done in duplicate,
site (underlined) and the missing nucleotide (boldface). A second and contained 10 M library compounds sourced from Maybridge
PCR reaction was performed using S3CDM and 3SP and Pwo DNA plc (Cornwall, UK), and peptide and 3CLpro as above. Wells con-
polymerase (Roche Applied Sciences) according to the manufactur- taining high and low controls, where neat DMSO was added instead
er’s conditions, using an annealing temperature of 50C. The re- of library compounds, were included on each microplate; buffer was
sulting amplicon was digested using BsmI and HindIII, and was used added to the reaction instead of 3CLpro for low controls. Primary
to replace the corresponding fragment in pT7HSP1. This yielded hits were defined as those compounds that reduced the activity of
pT7HSP2, whose nucleotide sequence was confirmed as described 3CLpro to half of the average residual activity of the high controls.
above. Activity Base (v. 5.0.5, ID Business Solutions Limited, Emeryville,
The his-tagged 3CLpro (ht-3CLpro) was expressed in E. coli GJ1158 CA), SARgen (v. 1.0, ID Business Solutions Limited), and Spotfire
freshly transformed with pT7HSP2. The cultures were grown to an DecisionSite (v. 7.1.1, Spotfire Inc., Somerville, MA) were used for
OD600 of 0.5 in LB with low salt before inducing the expression of data analysis. Compounds identified as primary hits were grouped
the protein by addition of 0.3 M NaCl. The cultures were incubated by functionality using ChemTree (v. 3.2.1, Golden Helix, Bozeman,
for an additional 12 hr before harvesting. MT); a representative compound from each cluster was selected
for secondary screening.
Protein Purification
All buffers were prepared using water purified on a Barnstead Secondary Screening
NANOpure UV apparatus to a resistivity of greater than 17 Mcm. The dose-response curves of the representative hits from primary
Unless otherwise specified, all manipulations involving the protein screening were determined by 3CLpro activity assays (as described
were performed at 4C. Cells from 4 liter of culture were harvested above), in the presence of seven concentrations of inhibitor (0.1–100
by centrifugation. The cell pellet (approximately 10 g) was washed M) and 100 M substrate. Data was fit to
twice with 500 ml of 20 mM sodium phosphate (pH 8.0), 10% glycerol
and then was resuspended in 10 ml of the same buffer, containing
v 
a
1   [I]IC50
s (2)1 mM MgCl2, 1 mM CaCl2, and 0.1 mg/ml DNase I. The cells were
disrupted by three successive passages through a French Press
(Spectronic Instruments Inc., Rochester, NY) using an operating
using GraFit (v. 4.0.10, Erithacus Software Ltd., Surrey, UK) (wherepressure of 20,000 p.s.i. The cell debris was removed by ultracentrif-
v is the background corrected reaction rate, a is the reaction rateugation at 37,000 rpm for 90 min in a T1250 rotor (DuPont Instru-
in the absence of inhibitor, [I] is the concentration of inhibitor, andments, Wilmington, DE). The clear supernatant fluid (raw extract)
s is the slope factor) to calculate IC50 values. Compounds exhibitingwas decanted.
sigmoidal semilogarithmic dose-response curves were tested by theThe raw extract (approximately 20 ml) was loaded onto a glass
described 3CLpro activity assay (with 31.2M of tested compound) inEcono-Column column (Bio-Rad, Hercules, CA) containing 5 ml of
the presence and absence of 0.01% (w/v) bovine serum albuminNi-NTA agarose resin (Qiagen Inc., Mississauga, ON, Canada) pre-
(BSA) (Sigma) and 1 mM 1,4-dithio-D,L-threitol (DTT) (BioShop Can-equilibrated with 20 mM sodium phosphate (pH 8.0) and 10% glyc-
ada Inc., Burlington, ON, Canada) in two separate studies. Thoseerol. The column was then washed by the successive passage of
compounds whose inhibition of 3CLpro was not affected by the pres-4 column volumes (CV) each of 20 mM sodium phosphate (pH 8.0);
ence of BSA or DTT were classified as secondary hits.20 mM sodium phosphate (pH 6.3) and 300 mM NaCl; and 20 mM
sodium phosphate (pH 8.0), 20 mM imidazole, and 300 mM NaCl.
The column was then washed with 2 CV of 20 mM sodium phosphate Evaluation of Hit Specificity
(pH 8.0) and 20 mM imidazole. The proteinase was eluted using The dose-response of the secondary hits was determined with pa-
2 CV of 20 mM sodium phosphate (pH 8.0) and 150 mM imidazole. pain (Calbiochem, La Jolla, CA), bovine pancreas chymotrypsin (Cal-
The eluted protein was exchanged into 50 mM Tris-HCl (pH 8.0) by biochem), Hepatitis A 3C proteinase (HAV 3Cpro) (purified according
performing three rounds of concentration-dilution using a stirred cell to [52]) and the Hepatitis C Nonstructural 3 proteinase (NS3pro) (181
concentrator equipped with a YM10 membrane (Amicon, Etobicoke, amino-terminal portion of the enzyme purified according to [46]) in
ON, Canada). The protein solution was concentrated to 16.8 mg/mL the presence of five to eleven concentrations of each inactivator (5
and frozen as beads in liquid nitrogen. A yield of 185 mg of ht-3CLpro nM–500 M). Activity assays for papain (5 nM) and chymotrypsin
was obtained from 4 liter of cell culture. Removal of the his-tag did (200 pM) were done at room temperature in a total volume of 50 l
not significantly affect 3CLpro cleavage activity. in black 384-well microplates (Corning, Corning, NY). Activity assays
for HAV 3Cpro (0.5 M) and NS3pro (0.23 M) were done in black
96-well microplates in a total volume of 200 l at 37C and 30C,SARS-CoV 3CLpro Kinetic Assay
SARS-CoV 3CLpro activity was measured by a quenched fluores- respectively. The substrate for papain and chymotrypsin was a ca-
sein derivative extensively labeled with the green-fluorescent BOD-cence resonance energy transfer (FRET) assay with the peptide
Chemistry & Biology
1452
IPY FL dye (Molecular Probes, Eugene, OR) (50 and 10 nM substrate rus in patients with Severe Acute Respiratory Syndrome. N.
Engl. J. Med. 348, 1967–1976.for papain and chymotrypsin assays, respectively). Substrates for
HAV 3Cpro and NS3pro were 10 M Dabcyl-GLRTQSND(Edans)G and 5. Fouchier, R.A.M., Kuiken, T., Schutten, M., van Amerongen, G.,
van Doornum, G.J.J., van den Hoogen, B.G., Peiris, M., Lim, W.,100 M Abz-DDIVPCSMSY(NO2)T, respectively. Enzyme activity for
all proteases was determined by the increase in fluorescence upon Sto¨hr, K., and Osterhaus, A.D.M.E. (2003). Koch’s postulates
fulfilled for SARS virus. Nature 423, 240.continuous monitoring of reactions using either the Analyst HT (Mo-
lecular Devices Corp.) or Victor2 (PerkinElmer, Woodbridge, ON, 6. Marra, M.A., Jones, S.J.M., Astell, C.R., Holt, R.A., Brooks-Wil-
son, A., Butterfield, Y.S.N., Khattra, J., Asano, J.K., Barber, S.A.,Canada) fluorescence plate readers. Excitation and emission wave-
lengths, respectively, for each proteinase assay were 485 and 530 Chan, S.Y., et al. (2003). The genome sequence of the SARS-
associated coronavirus. Science 300, 1399–1404.nm (papain and chymotrypsin), 355 and 460 nm (HAV 3Cpro), and
340 and 430 nm (NS3pro). Buffer systems for each protease were as 7. Rota, P.A., Oberste, M.S., Monroe, S.S., Nix, W.A., Campagnoli,
R., Icenogle, J.P., Pen˜aranda, S., Bankamp, B., Maher, K., Chen,follows: papain, 10 mM MES (pH 6.2), 200 mM NaCl, 2 mM EDTA,
and 1 mM DTT; chymotrypsin, 50 mM Tris/HCl (pH 7.8); HAV 3Cpro, M.-H., et al. (2003). Characterization of a novel coronavirus as-
sociated with Severe Acute Respiratory Syndrome. Science100 mM potassium phosphate (pH 7.5), and 2 mM EDTA; NS3pro, 50
300, 1394–1399.mM HEPES (pH 7.3), 150 mM NaCl, 0.1% Triton X-100, and 1 mM
8. World Health Organization (January 31, 2004). New case of labo-DTT. For the NS3pro activity assay, the enzyme was incubated with
ratory-confirmed SARS in Guangdong, China, update 5 (http://15 M 4A activating peptide (acetyl-KKKGSVVIVGRIILSGR-NH2) at
www.who.int/csr/don/2004_01_31/en/).30C for 15 min in reaction buffer, then incubated with inactivator
9. World Health Organization (April 30, 2004). China confirms SARSfor an additional 15 min before initiation of the reaction with sub-
infection in another previously reported case; summary of casesstrate. Dose-response data for these proteases with the secondary
to date, update 5 (http://www.who.int/csr/don/2004_04_30/en/).hits were fit to Equation 2 above, excluding HAV 3Cpro with MAC-
10. Thiel, V., Herold, J., Schelle, B., and Siddell, S.G. (2001). Viral5576, which was fit to
replicase gene products suffice for coronavirus discontinuous
transcription. J. Virol. 75, 6676–6681.
v 
a
1   [I]IC50
s  c (3) 11. Thiel, V., Ivanov, K.A., Putics, A´., Hertzig, T., Schelle, B., Bayer,
S., Weißbrich, B., Snijder, E.J., Rabenau, H., Doerr, H.W., et al.
(2003). Mechanisms and enzymes involved in SARS coronavirus
genome expression. J. Gen. Virol. 84, 2305–2315.(where c is the calculated background) since enzyme activity at the
12. Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J.R., and Hilgen-highest concentration of inhibitor did not fall to zero.
feld, R. (2003). Coronavirus main proteinase (3Clpro) structure:
basis for design of anti-SARS drugs. Science 300, 1763–1767.
Mass Spectrometry
13. Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L.,
The mass of each secondary hit was confirmed by the McMaster
Mo, L., Ye, S., Pang, H., et al. (2003). The crystal structures of
Regional Centre for Mass Spectrometry (Hamilton, ON, Canada)
severe acute respiratory syndrome virus main protease and
using a Quattro Ultima triple quadrupole mass spectrometer (Wa-
its complex with an inhibitor. Proc. Natl. Acad. Sci. USA 100,
ters/Micromass, Manchester, UK) using an electrospray ionization 13190–13195.
source. 14. Ziebuhr, J., Snijder, E.J., and Gorbalenya, A.E. (2000). Virus-
encoded proteinases and proteolytic processing in the Nidovi-
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